ANCA vasculitis is treated with a two-phase strategy: an aggressive remission-induction phase to stop active organ damage, followed by a longer maintenance phase to prevent relapse. The backbone of induction has traditionally been cyclophosphamide combined with glucocorticoids, but rituximab has emerged as an equally effective and sometimes preferable alternative. Newer additions like avacopan, a complement receptor blocker, are reshaping how clinicians minimize steroid exposure. The specifics depend on which subtype you have, which organs are involved, and how your body responds to initial therapy.
What Drives the Disease
ANCA vasculitis, also called ANCA-associated vasculitis (AAV), involves the immune system attacking small blood vessels throughout the body. The antibodies responsible target proteins inside neutrophils, the white blood cells that normally fight infection. When these anti-neutrophil cytoplasmic antibodies (ANCA) latch onto primed neutrophils, those cells become overactivated and release structures called neutrophil extracellular traps, or NETs. These are web-like tangles of DNA and antimicrobial proteins that, in healthy people, help capture bacteria. In AAV, excessive NET formation or poor clearance of those traps drives vascular damage and further immune activation.1PubMed Central. Neutrophil Extracellular Traps in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: Diagnostic and Clinical Significance-A Review of the Current Literature
NETs also activate the complement system, a cascade of proteins that amplifies inflammation. Specifically, NETs triggered by ANCA can kick-start the alternative complement pathway, creating a feedback loop: more complement activation leads to more neutrophil priming, which produces more NETs, which activates more complement.2PubMed Central. Neutrophil Extracellular Traps in ANCA-Associated Vasculitis3Clinical and Experimental Immunology. Neutrophil extracellular traps can activate alternative complement pathways This loop is the reason complement-targeted therapies like avacopan have a rationale in AAV, a point that becomes relevant when we get to newer treatment options.
PR3 Versus MPO and Why the Subtype Matters
AAV divides into three clinical diagnoses: granulomatosis with polyangiitis (GPA, formerly Wegener’s), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss). But treatment decisions increasingly hinge less on clinical diagnosis and more on which antibody you carry. PR3-ANCA (targeting proteinase 3) and MPO-ANCA (targeting myeloperoxidase) behave differently over time.
PR3-ANCA-positive patients tend to be diagnosed younger, are more likely to have ear, nose, and throat involvement, and face a higher risk of relapse. One randomized trial found that PR3-ANCA positivity and the presence of nonhemorrhagic lung disease at diagnosis were both associated with increased relapse risk.4PubMed. Risk of Relapse of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in a Randomized Controlled Trial of Plasma Exchange and Glucocorticoids A separate cohort study of over 200 patients confirmed that MPO-positive patients were older at diagnosis on average (about 67 versus 60 years) and that PR3-positive patients had more ear, nose, and throat symptoms. Interestingly, that study found no significant difference in relapse or remission rates between the two serotypes, which underscores that the picture is still being refined.5PubMed Central. Impact of different ANCA serotypes on the long-term outcome of ANCA-associated vasculitis patients The practical takeaway: ANCA subtype is one of several factors clinicians weigh when deciding how aggressive maintenance therapy should be and how long it should continue.
Remission Induction
The immediate goal in active AAV is remission induction, meaning suppressing the disease enough to halt organ damage. For decades, cyclophosphamide plus high-dose glucocorticoids was the standard. Rituximab changed that calculus. The landmark RAVE trial showed that rituximab was noninferior to cyclophosphamide overall, with about 64% of rituximab-treated patients achieving remission compared to 53% on cyclophosphamide. For patients with relapsing disease specifically, rituximab was clearly superior, with roughly two-thirds reaching remission compared to about 42% on cyclophosphamide.6PubMed Central. Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
A parallel trial (RITUXVAS) tested rituximab in patients with severe kidney involvement and found comparable sustained-remission rates between rituximab and cyclophosphamide, though rituximab did not prove superior in that setting. Adverse events were also similar between the two arms.7PubMed. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis Longer-term data from a multicenter Japanese cohort added a safety argument in rituximab’s favor: over 10 years, the rituximab group had significantly higher survival and no deaths from severe infection, compared to about 15% of cyclophosphamide-treated patients who died from infection.8PubMed Central. Long-term efficacy of rituximab versus intravenous cyclophosphamide for severe ANCA-associated vasculitis in multicenter REVEAL cohort study
Mycophenolate mofetil has been explored as a gentler induction alternative. A randomized trial found it noninferior to cyclophosphamide for achieving initial remission, with about 67% reaching remission on mycophenolate versus 61% on cyclophosphamide. The catch was a higher relapse rate afterward in the mycophenolate group, roughly a third compared to about a fifth on cyclophosphamide.9Annals of the Rheumatic Diseases. Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial For this reason, mycophenolate is generally reserved for milder presentations or situations where both rituximab and cyclophosphamide are unsuitable.
Reducing Steroid Burden
High-dose glucocorticoids remain central to induction, but their side effects are a major source of treatment-related harm. A randomized trial (PEXIVAS/LoVAS-related data) showed that when rituximab is used for induction, a reduced-dose glucocorticoid protocol achieves remission at the same rate as a conventional high-dose protocol. About 71% reached remission in the reduced-dose group and 69% in the high-dose group. The difference in safety was striking: serious adverse events occurred in roughly 19% of patients on reduced steroids versus 37% on high-dose steroids, and serious infections were about 7% versus 20%.10PubMed Central. Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial
Even the initial intravenous methylprednisolone pulse, which many protocols call for, can be safely lowered. A study found that patients given low-dose intravenous methylprednisolone had far fewer severe infections requiring hospitalization compared to those receiving the standard high dose.11PubMed Central. Low-Dose Intravenous Methylprednisolone in Remission Induction Therapy for ANCA-Associated Vasculitis The direction of the field is clear: use as little steroid as possible, for as short a time as possible, without sacrificing disease control.
Avacopan and Complement-Targeted Therapy
Avacopan is the first drug in AAV that targets the complement pathway directly. It blocks the C5a receptor on neutrophils, interrupting the inflammatory feedback loop described earlier. In a randomized trial, patients receiving avacopan instead of a standard prednisone taper (both groups also received rituximab) achieved sustained remission at one year in about 71% of cases, versus 56% in the prednisone taper group. The avacopan group also showed better recovery of kidney function, faster improvement in protein leaking into urine, and less glucocorticoid-related toxicity.12Annals of the Rheumatic Diseases. Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial Avacopan received regulatory approval in several countries starting in 2021 and represents a real shift toward steroid-free or steroid-minimal induction in the future, though its high cost and limited long-term data remain practical barriers.
Staying in Remission
Once active disease is controlled, the goal shifts to preventing relapse. AAV relapses frequently, especially in PR3-positive patients, so maintenance therapy typically lasts at least two years and sometimes much longer. Azathioprine was the traditional maintenance drug. Rituximab has replaced it in many cases after the MAINRITSAN trial showed dramatically lower relapse rates: about 5% of rituximab-treated patients had a major relapse by 28 months, versus 29% on azathioprine.13PubMed. Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis
The RITAZAREM trial confirmed this advantage specifically in patients with relapsing disease. Repeat-dose rituximab was superior to azathioprine for relapse prevention, with a hazard ratio strongly favoring rituximab.14PubMed Central. Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial For patients who do remain on azathioprine, the optimal duration is debated. A pooled analysis of long-term azathioprine data found that stopping after 18 months did not significantly increase relapse rates compared to continuing it longer, and that ANCA type had more influence on relapse-free survival than the duration of maintenance therapy.15Rheumatology. Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term follow-up data
The Role of Plasma Exchange
Plasma exchange, which physically removes circulating antibodies, was long used for severe AAV, particularly when the kidneys or lungs were in acute danger. The large PEXIVAS trial, involving over 700 patients, challenged that practice. Adding plasma exchange to standard treatment did not reduce the combined risk of death or end-stage kidney disease.16PubMed. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis
An updated meta-analysis painted a slightly more nuanced picture. Across seven trials with roughly a thousand participants, plasma exchange did reduce the risk of end-stage kidney disease at 12 months, but it also increased the risk of serious infections.17BMJ. The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis For severe lung bleeding specifically, an emulated target trial using PEXIVAS data found no mortality benefit from plasma exchange even in patients with serious alveolar hemorrhage.18PubMed. Plasma exchange for severe alveolar hemorrhage in antineutrophil cytoplasmic antibody-associated vasculitis: emulation of a target trial In practice, most centers now reserve plasma exchange for very specific situations rather than using it routinely.
Treating Eosinophilic Granulomatosis With Polyangiitis
EGPA stands apart from the other AAV subtypes because it involves eosinophils, a different type of white blood cell, and frequently overlaps with severe asthma. While rituximab and cyclophosphamide are used for serious EGPA flares, the biologic mepolizumab, which targets interleukin-5 (a protein that drives eosinophil production), has transformed management. The phase 3 MIRRA trial found that mepolizumab led to significantly more time in remission, with about 28% of treated patients accumulating at least 24 weeks of remission compared to 3% on placebo. The relapse rate was halved. Crucially, about 44% of mepolizumab-treated patients were able to reduce their daily steroid dose to 4 mg or less, compared to 7% on placebo.19PubMed Central. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
Real-world European data confirmed the drug works at both the 100 mg and 300 mg doses used in clinical practice.20PubMed Central. Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study Long-term follow-up from the MIRRA extension study showed that mepolizumab remained well tolerated over years of continuous use and sustained its steroid-sparing effect.21PubMed Central. Long-Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis For many EGPA patients, mepolizumab has meant freedom from the chronic high-dose steroids that previously defined their lives.
When Standard Treatments Fail
A small but meaningful number of AAV patients do not respond to rituximab or cyclophosphamide, or they relapse despite both. These refractory cases are among the most dangerous in rheumatology, and treatment options are limited. One emerging approach targets plasma cells, the immune cells that actually produce the harmful antibodies, using daratumumab, an anti-CD38 antibody originally developed for multiple myeloma. A case series described two patients with life-threatening, treatment-refractory AAV who were treated with daratumumab after failing both rituximab and cyclophosphamide. One patient had lung and kidney involvement that stabilized, and the other was on mechanical life support and dialysis but was eventually discharged home after treatment.22PubMed Central. Daratumumab for the treatment of refractory ANCA-associated vasculitis Two patients is far from proof, but for a disease where refractory cases can be fatal, it represents a plausible new direction awaiting formal trials.
Monitoring During Remission
Many patients and clinicians assume that tracking ANCA levels during remission can predict flares. The reality is less clear-cut. A meta-analysis found that a rising or persistently positive ANCA during remission is only modestly predictive of relapse, and serial ANCA measurements have limited use for guiding individual treatment decisions.23Rheumatology. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis—a meta-analysis That does not mean ANCA levels are useless; they provide a data point in context. But a rising titer alone is generally not enough to escalate treatment without other signs of clinical activity.
Newer biomarkers may eventually fill that gap. Urinary soluble CD163, a marker shed by activated macrophages in inflamed kidneys, has shown strong ability to distinguish active renal vasculitis from remission, with one study establishing a diagnostic cutoff that performed with high accuracy.24PubMed Central. The Clinical Application of Urine Soluble CD163 in ANCA-Associated Vasculitis Importantly, this marker stays low during “flare mimics” like nonvasculitic kidney injury, which is a problem that standard blood tests cannot reliably solve. Combining urinary CD163 with other markers like calprotectin and signs of blood in the urine further improves diagnostic accuracy.25Clinical Kidney Journal. Combining neutrophil and macrophage biomarkers to detect active disease in ANCA vasculitis: a combinatory model of calprotectin and urine CD163 Another study found that pairing urinary CD163 with a monocyte-related marker pushed the positive likelihood ratio for active renal vasculitis above 19, making it far more informative than ANCA titers alone.26PubMed Central. Urinary soluble CD163 and monocyte chemoattractant protein-1 in the identification of subtle renal flare in anti-neutrophil cytoplasmic antibody-associated vasculitis These tests are not yet standard in most clinics, but they are getting closer to routine use.
Infection Prevention and Vaccination Timing
The immunosuppressive drugs that control AAV also raise infection risk, and managing that tradeoff is a daily reality. Pneumocystis pneumonia, an opportunistic lung infection, is a particular concern during induction therapy. Standard practice in many centers is to prescribe preventive antibiotics, usually trimethoprim-sulfamethoxazole. The actual rate of infection appears low: one cohort study found no cases of Pneumocystis in AAV patients on rituximab maintenance, regardless of whether they received prophylaxis.27PubMed Central. Pneumocystis jirovecii Pneumonia Prophylaxis in Patients with ANCA Vasculitis on Rituximab Maintenance Therapy A larger study found the infection rate during induction to be about 15 cases per 1,000 patient-years, with no deaths. However, patients who received prophylaxis actually had higher rates of side effects like low white blood cell counts, rash, and kidney problems.28PubMed Central. Incidence of Pneumocystis Jiroveci Pneumonia in Patients With ANCA-Associated Vasculitis Initiating Therapy With Rituximab or Cyclophosphamide Whether to prescribe prophylaxis therefore involves weighing a low infection risk against the real possibility of drug side effects, and the answer varies by patient.
Vaccination is another area that requires careful choreography, especially for patients on rituximab. Because rituximab depletes B cells (the immune cells responsible for making antibodies in response to vaccines), vaccines given shortly after a rituximab dose are unlikely to produce a good immune response. Guidelines generally recommend vaccinating at least six months after the last rituximab infusion, and waiting at least four weeks after vaccination before giving the next rituximab dose. Measuring B cell levels before scheduling vaccines can help time things optimally, since B cell recovery varies substantially between individuals.29Nephrology Dialysis Transplantation. COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab
Pregnancy, Fertility, and Younger Patients
AAV is uncommon in younger adults, with the typical age of diagnosis above 50, but it does occur in women of childbearing age and even in children. For women considering pregnancy, the key challenge is managing the disease with medications safe for the fetus. Cyclophosphamide is toxic to the developing embryo and can cause infertility, so it is avoided in pregnancy planning. Rituximab, azathioprine, and glucocorticoids have more nuanced safety profiles, and planning ideally involves achieving stable remission before conception.30PubMed Central. Optimal management of ANCA-associated vasculitis before and during pregnancy: current perspectives
In pediatric patients, the disease tends to run a more relapsing course. A long-term follow-up study of children diagnosed with ANCA vasculitis found that all patients experienced relapse over time, with a median of four episodes. Kidney function was generally preserved, but treatment-related side effects were extensive: seven out of eight patients dealt with infections, and four were infertile, likely due to cyclophosphamide exposure.31PubMed Central. Long- term outcome of paediatric patients with ANCA vasculitis These findings have pushed pediatric practice toward rituximab-first approaches and earlier consideration of fertility preservation.
Living With AAV Beyond the Clinic
Disease control on paper does not always translate to feeling well. A study examining quality of life in AAV patients found that disease activity, unsurprisingly, worsened quality of life, anxiety, depression, and fatigue. But so did shorter disease duration, meaning people newly diagnosed often struggled more with mental health than those who had been living with the condition for years. Women reported more anxiety, and younger patients reported more fatigue regardless of disease activity.32PubMed Central. Exploration of health-related quality of life, anxiety and depression in antineutrophil cytoplasmic antibody-associated vasculitis These findings suggest that the first few years after diagnosis may warrant more proactive mental health support, not just immunosuppression.
For patients who do develop end-stage kidney disease, outcomes are better with kidney transplantation than with dialysis alone. Transplantation has the added benefit of reducing relapse risk because of the anti-rejection medications used. For patients who remain on dialysis, vasculitis flares are particularly difficult to treat because the immunosuppressive medications are poorly tolerated in that setting. Rituximab may have some advantages over cyclophosphamide in dialysis patients, partly because of its steroid-sparing properties for managing disease outside the kidneys.33Nephrology Dialysis Transplantation. End-stage renal disease in ANCA-associated vasculitis